Details of the presentation are as follows:
Abstract: 659
Title: Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: preclinical evidence and clinical data from the ARTISTRY-1 trial
Presenter: Ulka N. Vaishampayan, M.D., Professor, Internal Medicine,
Presentation Date: The poster, along with a pre-recorded presentation, will be available on the ASCO GI virtual meeting platform beginning
About Nemvaleukin Alfa ("nemvaleukin")
Nemvaleukin is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (IL-2) and the high affinity IL-2 alpha receptor chain, designed to preferentially expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by selectively binding to the intermediate-affinity IL-2 receptor complex. The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.
About the Nemvaleukin Clinical Development Program
ARTISTRY is an Alkermes-sponsored clinical development program evaluating nemvaleukin as a potential immunotherapy for cancer. The ARTISTRY program is comprised of multiple clinical trials evaluating intravenous and subcutaneous dosing of nemvaleukin, both as a monotherapy and in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. Ongoing trials in the ARTISTRY program include: ARTISTRY-1, ARTISTRY-2, ARTISTRY-3, ARTISTRY-6 and ARTISTRY-7.
About Alkermes plc
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,
Alkermes Contacts:
For Investors:
For Media: Sourojit Bhowmick, Ph.D., +1 781 609 6397
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-present-data-on-nemvaleukin-alfa-at-the-american-society-of-clinical-oncology-gastrointestinal-cancers-symposium-301461525.html
SOURCE